Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.
How this was made
The 30-second read
Why it matters
The divestiture completion and revised FY2026 ranges provide a new earnings framework for traders, with margin and EPS guidance narrowed and supported by BDS high-value solution growth.
Market read
Traders can reprice STVN based on the updated FY2026 revenue (€1.260b to €1.280b), adjusted EBITDA (€335.0m to €345.2m), and narrowed adjusted diluted EPS (€0.60 to €0.62) following the Balda divestiture.
What to watch
Negative free cash flow in Q2 (due to capex) and net debt level (€360.3m) could limit upside if investors prioritize cash conversion over adjusted EPS.
Background
Stevanato is a drug containment and delivery solutions provider, reporting Q2 2026 results and updating full-year guidance after selling its California-based Balda C. Brewer subsidiary.
Ticker impact
Stevanato reported Q2 2026 results and updated FY2026 guidance after completing the Balda C. Brewer divestiture and recording €12.2m sale costs.
Near-term bias upward if investors focus on higher organic growth and narrowed EPS range, but volatility possible around divestiture-related margin effects and free cash flow.
The article provides fresh, decision-relevant numbers: Q2 revenue/EBITDA/EPS, completion of the subsidiary sale, and revised FY2026 revenue, adjusted EBITDA, and adjusted diluted EPS ranges.
Market effects
Signals demand strength in drug containment and drug delivery systems via BDS high-value solution growth and Alina pen injector platform traction.
No direct regional macro impact; capex and ramp-up referenced in Italy, Indiana, Denmark, and Germany.
Customer regulatory approval for a liraglutide-based therapy in Europe supports the company’s international platform adoption narrative.
Counterpoint
The headline growth may be partly offset by Engineering segment weakness and divestiture-related margin drag, so the quality of earnings and cash generation may be less strong than adjusted metrics imply.
Key entities
- public_companyStevanato Group S.p.A.
Subject of the article, NYSE-listed as STVN, reporting Q2 2026 results and updated FY2026 guidance.
- subsidiaryBalda C. Brewer, Inc.
California-based subsidiary divested; sale and transaction costs of €12.2m recorded in Q2 2026.
- product_platformAlina pen injector platform
Stevanato’s proprietary drug delivery system referenced in a customer regulatory approval for a liraglutide-based therapy.
